article thumbnail

U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN

The Dermatology Digest

It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. Every treatment approval is hard-won, built on research, persistence, and partnership.

article thumbnail

Touchdown: Novartis Named First-ever Corporate Pharmaceutical Partner of the NFL

The Dermatology Digest

The partnership aims to empower football fans everywhere to make proactive decisions about their health, better understand screening guidelines and create a playbook for a healthier future. Novartis is the official first-in-category corporate pharmaceutical partner of the National Football League (NFL).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Green Lights New Stelara Biosimilar

The Dermatology Digest

Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of Selarsdi in the United States. The study was conducted in four countries in Europe and enrolled 581 patients.

article thumbnail

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology

The Dermatology Digest

via a strategic partnership with BENEV Company, Inc. Hugel, Benev Partner to Bring New Toxin to U.S. Hugel Inc.’s s botulinum toxin product Letybo is coming to the U.S. The two companies will collaborate in sales, marketing, education, and research. The goal is to capture approximately 10% of the U.S. market share within three years.

article thumbnail

La Roche-Posay and the Edge Launch Immersive Color Exhibit in NYC

The Dermatology Digest

SHADES was developed in partnership with the experiential designers at Makeout. Visitors will receive samples of La Roche-Posay’s Anthelios sun care products along with sun safety information. Shades at Edge will reinforce La Roche-Posay’s 2024 sunscreen campaign that aims to make Every Day A Sunscreen Day.

article thumbnail

Dermata, Revance Partner to Study Topical Application of Xyngari With Daxxify for Primary Axillary Hyperhidrosis

The Dermatology Digest

The Companies intend to first evaluate Xyngari with for the topical treatment of primary axillary hyperhidrosis and may explore additional indications through a broader partnership in the future. Dermata Therapeutics, Inc. and Revance Therapeutics, Inc.

article thumbnail

Learn Laser Hair Removal and IPL 

Lipgloss and Aftershave

Unlike large laser companies that spend millions on marketing with big events, influencer partnerships, and doctor endorsements, we avoid these costly strategies, which often contribute to significant price markups. Question Which of your lasers offers a “pain-free” experience for the client?